OraSure Technologies (OSUR)
(Delayed Data from NSDQ)
$4.32 USD
+0.09 (2.13%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $4.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.32 USD
+0.09 (2.13%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $4.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Zacks News
OraSure Technologies (OSUR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of -150.00% and 1.96%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies (OSUR) Earnings Expected to Grow: What to Know Ahead of Q2 Release
by Zacks Equity Research
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OraSure Technologies (OSUR) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 66.67% and 0.88%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies (OSUR) Earnings Expected to Grow: What to Know Ahead of Q1 Release
by Zacks Equity Research
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OraSure Technologies (OSUR) Q4 Earnings Miss Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of -57.14% and 7.35%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
OraSure Technologies (OSUR) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OraSure Technologies (OSUR) to Report Q4 Results: Wall Street Expects Earnings Growth
by Zacks Equity Research
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ResMed (RMD) Q2 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
ResMed (RMD) reported second-quarter fiscal 2021 revenues of $800 million, up 9% from a year ago.
Smith+Nephew's (SNN) PICO sNPWT Study Outcome Encouraging
by Zacks Equity Research
Smith+Nephew's (SNN) PICO Single Use Negative Pressure Wound Therapy System (sNPWT) considerably reduces surgical site infections complications and provides better patient outcome.
Allscripts (MDRX) Extends Tie-Up With US Orthopedic Alliance
by Zacks Equity Research
Allscripts (MDRX) extends strategic partnership with US Orthopedic Alliance to form a more scalable orhopedic services technology platform.
Hill-Rom (HRC) to Boost Cardiology Portfolio with New Buyout
by Zacks Equity Research
Hill-Rom's (HRC) acquisition of Bardy Diagnostics enables the former to expand into ambulatory cardiac monitoring space to accelerate digital health offering.
Aphria (APHA) Looks Good: Stock Adds 6% in Session
by Zacks Equity Research
Aphria (APHA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
OraSure Technologies (OSUR) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 114.29% and 11.38%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate OraSure Technologies (OSUR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Company News for Oct 20, 2020
by Zacks Equity Research
Companies in the news are: ONB, AMC, OSUR, BSRR
Implied Volatility Surging for OraSure (OSUR) Stock Options
by Zacks Equity Research
Investors need to pay close attention to OraSure (OSUR) stock based on the movements in the options market lately.
OraSure Technologies (OSUR) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of -77.78% and -14.54%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: OraSure Technologies (OSUR) Q2 Earnings Expected to Decline
by Zacks Equity Research
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: OraSure Technologies (OSUR) Q1 Earnings Expected to Decline
by Zacks Equity Research
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OraSure Technologies (OSUR) in Focus: Stock Moves 7.6% Higher
by Zacks Equity Research
OraSure Technologies (OSUR) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Analysts Estimate OraSure Technologies (OSUR) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OraSure Technologies (OSUR) Q3 Earnings Surpass Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 66.67% and -5.13%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: OraSure Technologies (OSUR) Q3 Earnings Expected to Decline
by Zacks Equity Research
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OraSure Technologies (OSUR) Q2 Earnings Top Estimates
by Zacks Equity Research
OraSure (OSUR) delivered earnings and revenue surprises of 133.33% and -6.94%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: OraSure Technologies (OSUR) Q2 Earnings Expected to Decline
by Zacks Equity Research
OraSure (OSUR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.